Aligos Therapeutics, Inc. (NASDAQ: ALGS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
Aligos Therapeutics, Inc. - Common stock (ALGS)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
ALGS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALGS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALGS alerts
High impacting Aligos Therapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ALGS
News
- Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024GlobeNewswire
- Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial ResultsGlobeNewswire
- Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024GlobeNewswire
- Aligos Therapeutics, Inc. (NASDAQ: ALGS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.MarketBeat
ALGS
Earnings
- 11/6/24 - Miss
ALGS
Sec Filings
- 11/19/24 - Form EFFECT
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- ALGS's page on the SEC website